Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200m.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition o. J Card Fail. 2021;27(4):2021.
   Web of Science ®Google Scholar
• Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–378.
   PubMed Web of Science ®Google Scholar
• Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12(3):323–333.
   PubMed Web of Science ®Google Scholar
• Gómez E. Capítulo 2. Introducción, epidemiología de la falla cardiaca e historia de las clínicas de falla cardiaca en Colombia. Rev Colomb Cardiol. 2015;23:6–12.
   Google Scholar
• Instituto Nacional de Salud - Observatorio Nacional de Salud. Primer informe observatorio nacional de salud - ONS: Aspectos relacionados con la frecuencia de uso de los servicios de salud, mortalidad y discapacidad en Colombia. Bogotá, D.C., Colombia: Imprenta Nacional de Colombia; 2011.
   Google Scholar
• Ciapponi A, Alcaraz A, Calderón M, et al. Burden of heart failure in Latin America: a systematic review and meta-analysis. Rev Española Cardiol. 2016;69(11):1051–1060.
   PubMed Web of Science ®Google Scholar
• Bloom MW, Greenberg B, Jaarsma T, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Prim. 2017;3:1–19.
   Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of Amer. J Card Fail. 2017;23(8):628–651.
   PubMed Web of Science ®Google Scholar
• McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37(4):531–546.
   PubMed Web of Science ®Google Scholar
• JJV M, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en salud. Bogotá: IETS; 2014.
   Google Scholar
• Banco de la República. PIB total y por habitante 2019(pr) a precios corrientes. 2020.
   Google Scholar
• JJV M, DeMets DL, Inzucchi SE, et al. The dapagliflozin and prevention of adverse‐outcomes in heart failure (DAPA‐HF) trial: baseline characteristics. Eur J Heart Fail. 2019;21(11):1402–1411.
   PubMed Web of Science ®Google Scholar
• Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age. Circulation. 2020;141(2):100–111.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). Prescribing information: dapagfliflozina (farxiga) [internet]. 2020 [ cited 2020 Sep 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf
   Google Scholar
• Saldarriaga C, Gómez J, Echeverría E Heart failure in Colombia: results form the RECOLFACA registry. Hear Fail 2019 [internet]. 2019. p. P2012. [cited 2021 Nov 07] Available from: https://esc365.escardio.org/presentation/193101?query=RECOLFACA https://esc365.escardio.org/presentation/193101?query=RECOLFACAttps://esc365.escardio.org/Congress/Heart-Failure-2019-6th-World-Congress-on-Acute-Heart-Failure/Poster-Session-4-Chronic-Heart-Failure-Epidemiology-Prognosis-Outcome/193101-heart-failure-in-colombia-results-form-the-recolfaca-registry
   Google Scholar
• Romero M, Arango CH. Analysis of cost effectiveness of the use of metoprolol succinate in the treatment of hypertension and heart failure in Colombia. Rev Colomb Cardiol. 2012;19:160–168.
   Google Scholar
• Atehortúa S, Senior JM, Castro P, et al. Cost-utility analysis of an implantable cardioverter-defibrillator for the treatment of patients with ischemic or non-ischemic New York heart association class II or III heart failure in Colombia. Biomedica. 2019;39(3):502–512.
   PubMed Web of Science ®Google Scholar
• Departamento Administrativo Nacional de Estadísticas (DANE). Estimaciones del cambio demográfico: tablas de vida completas y abreviadas por sexo y área a nivel nacional 2018–2070 y departamental 2018–2050 [Internet]. 2020 [ cited 2020 Mar 28]. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/estimaciones-del-cambio-demografico
   Google Scholar
• McEwan P, Darlington O, JJV M, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020;22(11):2147–2156.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA267]: ivabradine for treating chronic heart failure. [internet]. 2012 [ cited 2020 Oct 17]. Available from: https://www.nice.org.uk/guidance/ta267
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Technology appraisal guidance [TA388]: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. 2016.
   Google Scholar
• Welton N, Sutton A, Cooper N, et al. Evidence Synthesis for Decision Making in Healthcare. John Wiley & Sons, Ltd; New Jersey, United States. 2012.
   Google Scholar
• JJV M, Trueman D, Hancock E, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104(12):1006–1013.
   PubMed Web of Science ®Google Scholar
• Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Heal. 2012;15(5):708–715.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol Health States. Med Care. 1997;35(11):1095–1108.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud y Protección Social. Guía de Práctica Clínica para la prevención, diagnóstico, tratamiento y rehabilitación de la falla cardíaca en población mayor de 18 años clasificación B, C y D. Guía completa No.53 [GPC en Internet]. Edición 1. Bogotá D.C. [Internet]; 2016 [ cited 2020 Aug 19]. Available from: http://gpc.minsalud.gov.co/
   Google Scholar
• Ministerio de Salud y Protección Social (MSPS). Sismed - Sistema de información de precios de medicamentos. Reporte 2020. [Internet]; 2021 [ cited 2021 Apr 10]. Available from: http://www.sispro.gov.co/recursosapp/app/Pages/PreciosdeMedicamentos-Circular2de2012Excel.aspx
   Google Scholar
• Ministerio de Salud y de la Proteccion Social. Circular 10 de 2020. Por la cual se unifica y se adiciona el listado de los medicamentos sujetos al régimen de control directo de precios, se fija su precio máximo de venta, se actualiza el precio de algunos medicamentos conforme al Índice de precios [Internet]. 2020 [ cited 2021 Apr 10]. Available from: http://minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/circular-10-de-2020.pdf
   Google Scholar
• Mendoza F, Romero M, Lancheros J, et al. Financial burden of atrial defibrillation in Colombia. Rev Colomb Cardiol. 2020;27. 541–547.
   Google Scholar
• Departamento Administrativo Nacional de Estadísticas (DANE). Índice de precios al consumidor (IPC) - series de empalme, abril de 2020 [internet]. 2020 [ cited 2020 May 18]. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance [TA679]: dapagliflozin for treating chronic heart failure with reduced ejection fraction. [internet]. 2020 [ cited 2021 Apr 10]. Available from: https://www.nice.org.uk/guidance/ta679/documents/final-appraisal-determination-document
   Google Scholar
• Isaza N, Calvachi P, Raber I, et al. Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Network Open. 2021;4(7):e2114501.
   PubMed Web of Science ®Google Scholar
• Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6(8):926.
   PubMed Web of Science ®Google Scholar
• Di Tanna GL, Bychenkova A, O’Neill F, et al. Evaluating cost-effectiveness models for pharmacologic interventions in adults with heart failure: a systematic literature review. Pharmacoeconomics. 2019;37(3):359–389.
   PubMed Web of Science ®Google Scholar
• Raphael C, Briscoe C, Davies J, et al. Limitations of the New York heart association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007;93(4):476–482.
   PubMed Web of Science ®Google Scholar
• Gibelin P. An evaluation of symptom classification systems used for the assessment of patients with heart failure in France. Eur J Heart Fail. 2001;3(6):739–746.
   PubMed Web of Science ®Google Scholar
• Bennett JA, Riegel B, Bittner V, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Hear Lung J Acute Crit Care. 2002;31(4):262–270.
   PubMed Web of Science ®Google Scholar
• González CJ, Walker JH, Einarson TR. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Pan Am J Public Heal. 2009;26:55–63.
   Web of Science ®Google Scholar
• TamayoD C, Rodríguez VA, Rojas MX, et al. Costos ambulatorios y hospitalarios de la falla cardiaca en dos hospitales de Bogotá. Acta Médica Colomb. 2013;38:208–212.
   Google Scholar
• Enciso A Evaluación económica de los dispositivos médicos utilizados en el tratamiento de diabetes en Colombia. 2016.
   Google Scholar
• Perlaza JG, Regino EAG, Lozano AT, et al. Costos de las Fracturas en mujeres con Osteoporosis en Colombia. Acta Médica Colomb. 2014;39. 46–56.
   Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–1534.
   PubMed Web of Science ®Google Scholar
• Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–470.
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health States of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mak. 2002;22(4):340–349.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud y Protección Social. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de los pacientes mayores de 15 años con diabetes mellitus tipo 1. 2016 [Internet]. 2016 [ cited 2020 Aug 19]. Available from: http://gpc.minsalud.gov.co/
   Google Scholar